IMMX
Price:
$1.97
Market Cap:
$54.08M
Immix Biopharma, Inc., a clinical-stage biopharmaceutical company, engages in developing various tissue-specific therapeutics in oncology and inflammation in the United States and Australia. The company is developing IMX-110 that is in Phase 1b/2a clinical trials for the treatment of soft tissue sarcoma and solid tumors; IMX-111, a tissue-specific biologic for the treatment of colorectal cancers; and IMX-120, a tissue-specific biologic for the treatment of ulcerative colitis and severe Crohn's disease. It has a clinical collaboration and supply agreement with BeiGene Ltd. for a combination Phase 1b clinical trial in solid tumors of IMX-110 and anti-PD-1 Tislelizumab. The company was incorpor...[Read more]
Industry
Biotechnology
IPO Date
2021-12-16
Stock Exchange
NASDAQ
Ticker
IMMX
According to Immix Biopharma, Inc.’s latest financial reports and current stock price. The company's current PE Ratio is -2.29. This represents a change of -46.77% compared to the average of -4.30 of the last 4 quarters.
The mean historical PE Ratio of Immix Biopharma, Inc. over the last ten years is -13.51. The current -2.29 PE Ratio has changed 1.59% with respect to the historical average. Over the past ten years (40 quarters), IMMX's PE Ratio was at its highest in in the December 2021 quarter at -0.30. The PE Ratio was at its lowest in in the September 2020 quarter at -59.75.
Average
-13.51
Median
-7.78
Minimum
-29.33
Maximum
-1.93
Discovering the peaks and valleys of Immix Biopharma, Inc. PE Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 111.33%
Maximum Annual PE Ratio = -1.93
Minimum Annual Increase = -92.23%
Minimum Annual PE Ratio = -29.33
Year | PE Ratio | Change |
---|---|---|
2023 | -7.78 | 111.33% |
2022 | -3.68 | 90.59% |
2021 | -1.93 | -92.23% |
2020 | -24.85 | -15.25% |
The current PE Ratio of Immix Biopharma, Inc. (IMMX) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages
3-year avg
-4.46
5-year avg
-13.51
10-year avg
-13.51
Immix Biopharma, Inc.’s PE Ratio is less than ZyVersa Therapeutics, Inc. (-0.10), less than Hepion Pharmaceuticals, Inc. (-0.15), less than AVROBIO, Inc. (2.07), less than eFFECTOR Therapeutics, Inc. (-0.00), less than CNS Pharmaceuticals, Inc. (-0.00), less than Navidea Biopharmaceuticals, Inc. (0.03), less than Sonnet BioTherapeutics Holdings, Inc. (-0.55), less than Freeline Therapeutics Holdings plc (0), less than Enveric Biosciences, Inc. (-0.57), less than CohBar, Inc. (-0.36), less than Elevation Oncology, Inc. (-0.20), less than Ocean Biomedical, Inc. (-0.93), less than null (-0.17),
Company | PE Ratio | Market cap |
---|---|---|
-0.10 | $2.70M | |
-0.15 | $4.20M | |
2.07 | $5.24M | |
-0.00 | $188.18K | |
-0.00 | $4.60M | |
0.03 | $100.08K | |
-0.55 | $4.53M | |
0 | $28.28M | |
-0.57 | $4.53M | |
-0.36 | $1.25M | |
-0.20 | $36.94M | |
-0.93 | $33.96M | |
-0.17 | $0 |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Immix Biopharma, Inc. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like Immix Biopharma, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the PE Ratio?
How can you use the PE Ratio?
What is Immix Biopharma, Inc.'s PE Ratio?
How is the PE Ratio calculated for Immix Biopharma, Inc. (IMMX)?
What is the highest PE Ratio for Immix Biopharma, Inc. (IMMX)?
What is the 3-year average PE Ratio for Immix Biopharma, Inc. (IMMX)?
What is the 5-year average PE Ratio for Immix Biopharma, Inc. (IMMX)?
How does the current PE Ratio for Immix Biopharma, Inc. (IMMX) compare to its historical average?